We are live on ! Find out more
PAP

Persistent Asset Partners Portfolio holdings

AUM $335M
1-Year Est. Return 275.57%
This Fund
S&P 500
This Quarter Est. Return
+39.3%
1 Year Est. Return
+275.57%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$223M
AUM Growth
+$77.2M
Cap. Flow
+$50.2M
Cap. Flow %
22.55%
Top 10 Hldgs %
25.3%
Holding
464
New
223
Increased
67
Reduced
60
Closed
103

Top Buys

Rank Stock Value
1
MOH icon
Molina Healthcare
MOH
+$8.43M
2
ELV icon
Elevance Health
ELV
+$5.15M
3
INTC icon
Intel
INTC
+$4.26M
4
SNDK
Sandisk
SNDK
+$3.61M
5
JNJ icon
Johnson & Johnson
JNJ
+$3.5M

Top Sells

Rank Stock Value
1
IEF icon
iShares 7-10 Year Treasury Bond ETF
IEF
+$4.82M
2
UNH icon
UnitedHealth
UNH
+$3.15M
3
IBIT icon
iShares Bitcoin Trust
IBIT
+$2.87M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$2.84M
5
LH icon
Labcorp
LH
+$2.58M

Sector Composition

Rank Sector Weight
1 Healthcare 52.36%
2 Technology 13.57%
3 Financials 11.27%
4 Miscellaneous 7.53%
5 Communication Services 4.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
151
Ascendis Pharma A/S
ASND
$17.7B
$391K 0.18%
1,832
-4,498
-71% -$929K
HRMY icon
152
Harmony Biosciences
HRMY
$2.46B
$390K 0.18%
10,434
-1,066
-9% -$35K
SLB icon
153
SLB Ltd
SLB
$85.3B
$384K 0.17%
+10,000
New +$363K
VIR icon
154
Vir Biotechnology
VIR
$1.93B
$383K 0.17%
+63,550
New +$378K
MPLT
155
MapLight Therapeutics
MPLT
$639M
$382K 0.17%
+21,766
New +$365K
COR icon
156
Cencora
COR
$63.2B
$378K 0.17%
+1,119
New +$381K
AMLX icon
157
Amylyx Pharmaceuticals
AMLX
$3.8B
$376K 0.17%
31,147
+8,234
+36% +$112K
KTTA icon
158
Pasithea Therapeutics
KTTA
$19.4M
$375K 0.17%
+290,555
New +$255K
AVBH
159
Avidbank Holdings
AVBH
$351M
$373K 0.17%
14,033
-16,097
-53% -$418K
AMZN icon
160
Amazon
AMZN
$2.79T
$369K 0.17%
+1,600
New +$366K
MRK icon
161
Merck
MRK
$371B
$365K 0.16%
+3,471
New +$326K
LQDA icon
162
Liquidia Corp
LQDA
$6.15B
$363K 0.16%
+10,536
New +$300K
SNY icon
163
Sanofi
SNY
$106B
$361K 0.16%
+7,445
New +$369K
ZYME icon
164
CALL
Zymeworks
ZYME
$2.09B
$359K 0.16%
649
+198
+44% +$4.32K
XERS icon
165
Xeris Biopharma Holdings
XERS
$1.56B
$358K 0.16%
45,609
+28,407
+165% +$224K
ARDX icon
166
Ardelyx
ARDX
$976M
$353K 0.16%
60,490
-31,556
-34% -$176K
GLUE icon
167
Monte Rosa Therapeutics
GLUE
$1.18B
$348K 0.16%
+22,211
New +$299K
SLNO
168
DELISTED
Soleno Therapeutics
SLNO
$343K 0.15%
7,416
-33,843
-82% -$1.86M
RIGL icon
169
Rigel Pharmaceuticals
RIGL
$909M
$342K 0.15%
+7,995
New +$301K
NTRA icon
170
Natera
NTRA
$47.3B
$340K 0.15%
+1,484
New +$310K
WVE icon
171
Wave Life Sciences
WVE
$958M
$337K 0.15%
+19,827
New +$201K
PCRX icon
172
Pacira BioSciences
PCRX
$1.05B
$335K 0.15%
12,962
-613
-5% -$14.6K
INCY icon
173
PUT
Incyte
INCY
$25.7B
$329K 0.15%
+266
New +$25.7K
JAZZ icon
174
CALL
Jazz Pharmaceuticals
JAZZ
$16B
$329K 0.15%
283
+54
+24% +$8.28K
GOSS icon
175
CALL
Gossamer Bio
GOSS
$85.7M
$328K 0.15%
2,401
+472
+24% +$1.35K
5 6
7
8 9

Similar funds

JWM
Jessup Wealth Management Dayton, Ohio $335M AUM 56.2% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $335M AUM 97.32% 1-Year Est. Return
TFA
TPG Financial Advisors Portland, Oregon $335M AUM 14.14% 1-Year Est. Return
SIM
Seaview Investment Managers Miami, Florida $335M AUM 47.2% 1-Year Est. Return
OWM
OneAscent Wealth Management Birmingham, Alabama $336M AUM 20.38% 1-Year Est. Return
SS
Spinecap SAS Paris, France $335M AUM 16.94% 1-Year Est. Return
BIA
BHK Investment Advisors Birmingham, Alabama $335M AUM 20.89% 1-Year Est. Return
ATC
Adirondack Trust Company Saratoga Springs, New York $336M AUM 29.2% 1-Year Est. Return

Persistent Asset Partners's Q4 2025 Portfolio in Review

As of Q4 2025, Persistent Asset Partners held 464 positions worth $223M, up 53% from $145M the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Persistent Asset Partners deployed $50.2M of net new capital in Q4 2025, opening 223 new positions and adding to 67 existing holdings. Its largest new stake was Molina Healthcare: 51,285 shares worth $8.9M.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, up from 49% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was UnitedHealth, an estimated $3.15M trimmed.

  • Persistent Asset Partners's largest Q4 2025 buy was Molina Healthcare: 51,285 shares worth $8.9M.
  • Persistent Asset Partners added most to Elevance Health in Q4 2025, an estimated $5.15M increase.
  • Persistent Asset Partners's biggest Q4 2025 reduction was UnitedHealth, cutting an estimated $3.15M.
  • Persistent Asset Partners fully exited iShares 7-10 Year Treasury Bond ETF in Q4 2025, selling an estimated $4.82M.
  • Persistent Asset Partners's ten largest holdings make up 25% of its $223M portfolio in Q4 2025.
  • Persistent Asset Partners opened 223 new positions and closed 103 in Q4 2025.
  • Persistent Asset Partners's portfolio value rose 53% quarter-over-quarter to $223M.

Based on Persistent Asset Partners's 13F filing for Q4 2025, filed 17 Feb 2026.